Aditya Akshaya Bio Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 5 Year, 4 Months
- Last Filing with ROC 31 Mar 2021
- Revenue Growth %
- Profit Growth -1287.34%
- Ebitda -1287.34%
- Net Worth -247.13%
- Total Assets 43.77%
About Aditya Akshaya Bio Pharma
Aditya Akshaya Bio Pharma Private Limited (AABPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 October 2019 (Five years and four months 1 days old ). Its registered office is in Visakhapatnam, Andhra Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Satyanarayana Mantena, Lakshmipathi Raju, and Seetharamaraju Jampana serve as directors at the Company.
Company Details
-
Location
Visakhapatnam, Andhra Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232AP2019PTC113135
-
Company No.
113135
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
16 Oct 2019
-
Date of AGM
30 Nov 2021
-
Date of Balance Sheet
31 Mar 2021
-
Listing Status
Unlisted
-
ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Aditya Akshaya Bio Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Satyanarayana Mantena
|
Managing Director | 24-Oct-2019 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Lakshmipathi Raju
|
Director | 14-Oct-2020 | Current |
|
Seetharamaraju Jampana
|
Director | 16-Oct-2019 | Current |
Financial Performance of Aditya Akshaya Bio Pharma.
Aditya Akshaya Bio Pharma Private Limited, for the financial year ended 2021, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1287.34% decrease in profit. The company's net worth observed a substantial decline by a decrease of 247.13%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aditya Akshaya Bio Pharma?
In 2021, Aditya Akshaya Bio Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Silicon Cable Industries Private LimitedSatyanarayana Mantena is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aditya Akshaya Bio Pharma?
Unlock and access historical data on people associated with Aditya Akshaya Bio Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aditya Akshaya Bio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aditya Akshaya Bio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
